



OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS

**Health Care Services and Products Division
Bureau of Competition
Federal Trade Commission
Washington D.C. 20580**

**Markus H. Meier
Assistant Director**

**David R. Pender
Deputy Assistant Director**

**Bradley S. Albert
Deputy Assistant Director**

April 2006

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS	3
A. Monopolization	3
B. Agreements Not to Compete	5
C. Agreements on Price or Price-Related Terms	9
D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing	14
E. Illegal Tying and Other Arrangements	14
III. PHARMACEUTICAL MERGERS	14
A. Horizontal Mergers between Direct Competitors	14
B. Potential Competition Mergers	30
C. Innovation Market Mergers	33
D. Vertical Mergers	34
IV. INDUSTRY GUIDANCE STATEMENTS	35
A. Advisory Opinions	35
B. Citizen Petition to the Food and Drug Administration	35
V. AMICUS BRIEFS	36
A. Table of Cases	38
B. Table of Briefs	43

